Literature DB >> 16305999

Reactivity of valganciclovir in aqueous solution.

Dimitrios Stefanidis1, Michael Brandl.   

Abstract

The rates of hydrolysis of valganciclovir to ganciclovir and L-valine and isomerization of the R and S diastereomers of valganciclovir in aqueous buffer solution from pH 3.8 to 11.5 were determined at 37 degrees C. The kinetics of hydrolysis were first order for at least two half-lives in neutral and basic solutions. In acidic solutions where less than 10% degradation occurred, the rate of hydrolysis was determined assuming a first-order loss in drug. At 37 degrees C and pH 7.08, the half life is 11 h. The maximum stability at the pH values studied occurred at pH 3.81 with a half life of 220 days. The kinetics of the approach to equilibrium for the isomerization were first order and the ratio of the R:S isomer at equilibrium was 52:48. Isomerization was approximately 10 fold faster than hydrolysis over the pH range studied with a half-life at pH 7.01 of 1 h. The maximum stability toward isomerization (t1/2>533 h) occurs at a pH below 3.8. The pH-rate profile for the hydrolysis and the isomerization reaction are best described by hydroxide ion catalyzed mechanisms. In acidic and neutral solutions, the hydroxide reacts with the protonated form of the drug, while in basic solutions, the hydroxide reacts with the neutral form of the drug.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16305999     DOI: 10.1080/03639040500271951

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  5 in total

1.  Development of an appropriate simple suspension method for valganciclovir medication.

Authors:  Yasuyuki Masaoka; Yoichi Kawasaki; Ryo Kikuoka; Atsushi Ogawa; Satoru Esumi; Yudai Wada; Soichiro Ushio; Yoshihisa Kitamura; Toshiaki Sendo
Journal:  J Pharm Health Care Sci       Date:  2020-07-07

2.  A Physiologically Based Pharmacokinetic Model for Ganciclovir and Its Prodrug Valganciclovir in Adults and Children.

Authors:  V Lukacova; P Goelzer; M Reddy; G Greig; B Reigner; N Parrott
Journal:  AAPS J       Date:  2016-07-22       Impact factor: 4.009

3.  L-valine ester of cyclopropavir: a new antiviral prodrug.

Authors:  Zhimeng Wu; John C Drach; Mark N Prichard; Milka Yanachkova; Ivan Yanachkov; Terry L Bowlin; Jiri Zemlicka
Journal:  Antivir Chem Chemother       Date:  2009-09-25

4.  Pharmacokinetics of ganciclovir and valganciclovir in the adult horse.

Authors:  R J Carmichael; C Whitfield; L K Maxwell
Journal:  J Vet Pharmacol Ther       Date:  2013-01-10       Impact factor: 1.786

5.  High Throughput Screening of Valganciclovir in Acidic Microenvironments of Polyester Thin Films.

Authors:  Teilo Schaller; Tobias Wenner; Rupesh Agrawal; Stephen Teoh; Li Ting Phua; Joachim S C Loo; Terry W J Steele
Journal:  Materials (Basel)       Date:  2015-04-13       Impact factor: 3.623

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.